MannKind Corporation (NNFN)
XFRA 
Summary
NNFN Chart
2026 Outlook: Afrezza, Furoscix, And MannKind's Path To Revenue Expansion
MannKind Corporation is transitioning from a volatile biotech to a diversified, revenue-driven pharma, with FUROSCIX and Afrezza driving commercial momentum. MNKD's 2026 business outlook highlights expanding commercial assets, key regulatory milestones, and a strong pipeline, positioning 2026 as a potential breakout year. Afrezza's FDA label update removes adoption barriers, expanding its addressable market and supporting MNKD's long-term growth thesis.
MannKind (MNKD) Upgraded to Strong Buy: Here's What You Should Know
MannKind (MNKD) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
MannKind's ReadyFlow Autoinjector: A Game Changer For Heart Failure Patients
MannKind Corporation delivered strong Q3 '25 results, beating EPS and revenue estimates, and shares have responded positively. The FDA accepted the supplemental New Drug Application for the FUROSCIX ReadyFlow Autoinjector, offering rapid furosemide delivery for CHF and CKD patients. I see a substantial TAM, estimating 670,000 to 1.34 million potential U.S. heart failure patients for ReadyFlow, with significant revenue implications.
MannKind Corporation (NNFN) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
What is the earnings per share?
When is the next earnings date?
Has MannKind Corporation ever had a stock split?
MannKind Corporation Profile
| Biotechnology Industry | Healthcare Sector | Michael E. Castagna CEO | XFRA Exchange | US56400P7069 ISIN |
| US Country | 403 Employees | - Last Dividend | 3 Mar 2017 Last Split | 28 Jul 2004 IPO Date |
Overview
MannKind Corporation is a pioneering biopharmaceutical company with a primary focus on creating and commercializing inhaled therapeutic products aimed at treating endocrine and orphan lung diseases primarily within the United States. The company has carved a niche in the healthcare sector by offering innovative solutions like Afrezza, an inhaled insulin, and the V-Go wearable insulin delivery device for adults with diabetes, showcasing its commitment to improving the quality of life for patients with chronic conditions. Beyond its current offerings, MannKind is engaged in the development of an exciting pipeline of products intended for the treatment of a variety of serious pulmonary conditions. Through strategic collaborations and agreements with companies such as United Therapeutics Corporation, Vertice Pharma, and Cipla Ltd., as well as partnerships for the commercialization of its products in international markets like Brazil and India, MannKind Corporation continues to expand its global footprint and impact. Founded in 1991 and based in Danbury, Connecticut, the company is a testament to the enduring pursuit of innovation in the healthcare industry.
Products and Services
- Afrezza
An innovative inhaled insulin product designed to improve glycemic control in adults suffering from diabetes. This product exemplifies MannKind's leadership in developing inhaled therapeutic solutions for chronic diseases.
- V-Go Wearable Insulin Delivery Device
A cutting-edge solution for adults with diabetes, providing a continuous subcutaneous infusion of insulin. This device highlights MannKind's dedication to improving diabetes management through innovative technology.
- Tyvaso DPI (Treprostinil)
An inhalation powder in development for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. This collaboration with United Therapeutics Corporation showcases MannKind's focus on addressing severe pulmonary diseases through advanced inhalation technologies.
- MNKD-101
A nebulized formulation of clofazimine under development for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease, demonstrating MannKind's commitment to combating complex pulmonary conditions.
- MNKD-201
A dry-powder formulation of nintedanib being developed for the treatment of idiopathic pulmonary fibrosis (IPF), highlighting MannKind's innovative approach to addressing fibrotic lung diseases.
- Collaborations and Agreements
MannKind Corporation has established essential collaborations and licensing agreements aimed at the development, regulatory approval, and commercialization of its products. Notable partnerships include a co-promotion agreement with Vertice Pharma for Thyquidity and collaborations with Thirona, Biomm S.A., and Cipla Ltd. for the global distribution and marketing of Afrezza. These strategic alliances underscore MannKind's global outreach and its commitment to making its life-changing therapies available worldwide.
